• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Who made 100% in MS Division

Quote
Anonymous said:
What makes you think they would hire you. Having MS experience at Novartis is worthless everybody knows that.
Click to expand...

because thank to god I have 7 years of prior MS experience and unlike most who jumped ship at first chance, I only jump when Im passionate about a certain drug. I think Gilenya is a great therapy, thats the only reason Im still hear now.
 




Anonymous said:
because thank to god I have 7 years of prior MS experience and unlike most who jumped ship at first chance, I only jump when Im passionate about a certain drug. I think Gilenya is a great therapy, thats the only reason Im still hear now.
Click to expand...

You must like being lied to and getting screwed every trimester. Gilenya is a great drug but we work for the worst company. If you are that good I doubt you will stay for 1 drug.
 




Anonymous said:
You must like being lied to and getting screwed every trimester. Gilenya is a great drug but we work for the worst company. If you are that good I doubt you will stay for 1 drug.
Click to expand...

"we work for the worst company" ......sounds like you're still here numb nuts. I will only jump ship for the right position because the alternative is making a good base and barely working.
 




Anonymous said:
"we work for the worst company" ......sounds like you're still here numb nuts. I will only jump ship for the right position because the alternative is making a good base and barely working.
Click to expand...

You lazy ass just quit. I have 100 people ready to take your job tomorrow. It's assholes like you who make close to 200K a year and still complain. Nothing will make people like you happy. Go start you own business and get the hell out LOSER!
 




Anonymous said:
You lazy ass just quit. I have 100 people ready to take your job tomorrow. It's assholes like you who make close to 200K a year and still complain. Nothing will make people like you happy. Go start you own business and get the hell out LOSER!
Click to expand...

Keep drinking the Kool Aid and hopefully someday you will be able to perform for your wife! BTW the only people that will come to Novartis MSBU are the unemployed or unemployable. I will stay and take the money
 








Anonymous said:
Keep drinking the Kool Aid and hopefully someday you will be able to perform for your wife! BTW the only people that will come to Novartis MSBU are the unemployed or unemployable. I will stay and take the money
Click to expand...

Your family must very proud of you. Your wife must love seeing you in boxers watching ESPN at 2 in the afternoon. I bet you are home before your kids get off the bus . TOTAL LOSER
 












Getting a lawyer this week after my offer is made to get out of here with a new company.....we found a loop hole in the payout and kicker bonus that was rolled out. Will post in a few days and Novartis will be paying A LOT of people money owed!!!!!
 








Anonymous said:
Getting a lawyer this week after my offer is made to get out of here with a new company.....we found a loop hole in the payout and kicker bonus that was rolled out. Will post in a few days and Novartis will be paying A LOT of people money owed!!!!!
Click to expand...

Ya ok sure. Go ahead and sue Novartis. Like fighting city hall you dope. Get on with your life and chalk it up to a bad decision you made in your life.
 












I can't believe how bad this division has become.Micro management at all levels.Obviously the marketing plan is not working. Obviously the Account Managers, NE, and Sales Specialists are not happy or motivated. It is bad and instead of making changes the real issues are ignored,Disappointment at leadership and their ability to adapt to competition.Aubagio is now logging more weekly SRFs.
 




We have no leadership. Dagmar is clueless and Randi can only blog about side effects of Techfidera. Time is running out and now nasty adverse events are starting to appear. Every rep wants out we all just waiting for a better opportunity. The June meeting will be sad and pathetic.
 




Everyone I talk to has NO interest in going to this meeting, waste of two days....... Morale is at ZERO, people getting screwed out of bonus and kickers, lies, micro managing primary care managers passing themselves off as MS managers, more lies, cluster screw marketing, and still more LIES.........
 




TO PULL UP GRAPHS GO TO KEYWORDS UNDER NEWS "BIOGEN FORBES"
JUST AMAZING!!!!
GILENYA GOALS ARE INCREASED BY OVER 25% IN T3.



Biogen Idec's MS Drug Launch Is Going Amazingly Well. These Two Graphs Prove It


Biogen Idec BIIB -0.14% shares are up 60% since I profiled the company in Forbes in December. The reason’s pretty simple: sales of the MS drug Tecfidera are basically destroying what were already very high expectations. Mark Schoenebaum at International Strategy & Investment Group noted on Tuesday that according to data from IMS Health, prescriptions for Tecfidera went up 21% last week. Even if patients start dropping off the drug at a 10% rate and weekly additions slow, sales could still hit $800 million this year, about double what analysts had expected before the launch. This graph is Schoenebaum’s, and it compares Tecfidera’s launch to those of Novartis ‘ Gilenya and Sanofi ‘s Aubagio, the other new MS pills.


Courtesy ISI Group

But that’s not the only piece of good news, from Cowen & Company analyst Eric Schmidt. It appears that the MS drug market is growing, not shrinking. Many investors feared that Tecfidera would cannibalize sales of Avonex, another Biogen MS drug. So far, that’s not happening. This graph comes from Schmidt:


Courtesy Cowen & Co.
 








Anonymous said:
TO PULL UP GRAPHS GO TO KEYWORDS UNDER NEWS "BIOGEN FORBES"
JUST AMAZING!!!!
GILENYA GOALS ARE INCREASED BY OVER 25% IN T3.



Biogen Idec's MS Drug Launch Is Going Amazingly Well. These Two Graphs Prove It


Biogen Idec BIIB -0.14% shares are up 60% since I profiled the company in Forbes in December. The reason’s pretty simple: sales of the MS drug Tecfidera are basically destroying what were already very high expectations. Mark Schoenebaum at International Strategy & Investment Group noted on Tuesday that according to data from IMS Health, prescriptions for Tecfidera went up 21% last week. Even if patients start dropping off the drug at a 10% rate and weekly additions slow, sales could still hit $800 million this year, about double what analysts had expected before the launch. This graph is Schoenebaum’s, and it compares Tecfidera’s launch to those of Novartis ‘ Gilenya and Sanofi ‘s Aubagio, the other new MS pills.


Courtesy ISI Group

But that’s not the only piece of good news, from Cowen & Company analyst Eric Schmidt. It appears that the MS drug market is growing, not shrinking. Many investors feared that Tecfidera would cannibalize sales of Avonex, another Biogen MS drug. So far, that’s not happening. This graph comes from Schmidt:


Courtesy Cowen & Co.
Click to expand...


No chance of hitting goals moving forward Time to jump ship
 




Top Bottom
Back
Quote